Efficacy of Sparex in the management of intestinal motility disorders

Abstract

Irritable bowel syndrome (IBS) is one of the most common functional bowel diseases. What is more, a number of digestive diseases are characterized by symptoms similar to those observed in IBS. The principles of treatment of IBS and IBS-related disorders are same. The key symptom of IBS - abdominal pain - is developed as a result of spasmodic or hyperkinetic dyskinesia, so the main group of drugs to be used in the treatment are antispasmodics. Preference is given to selective antispasmodics. Sparex is a national generic of the selective intestinal antispasmodic mebeverine hydrochloride which has been known since 1965, and is characterized by the most affordable price among analogues. The study which included 48 patients demonstrated high efficacy of Sparex administered for 4 weeks in a dosage of 200 mg twice daily for relief of pain, flatulence and stool normalization both in IBS and IBS-related disorders. Good and satisfactory results evaluated by a 3-point scale were achieved in 87.5% of patients. The results allowed to conclude that the medicine, apart from its strong antispasmodic effect, also provided a eukinetic action - normalization of the transit of chyme in the intestine both in constipation and diarrhea. Normalization of stool was observed in 77.2% of patients with both constipation and diarrhea, and in the rest of patients the severity of stool disorders decreased by more than 1 point. In the course of the study, no side effects were observed while taking Sparex.

Keywords

• синдром раздраженного кишечника
• (срк)
• срк-подобные нарушения
• абдоминальная боль
• мебеверина гидрохлорид
• спарекс
• irritable bowel syndrome (ibs)
• ibs-related disorders
• abdominal pain
• mebeverine hydrochloride
• sparex